Search clinical trials for: GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vac

Total 61 results

GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds

Infections, Meningococcal

Thailand, Panama, Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland, Germany, Hungary, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Meningococcal Immunisation (Healthy Volunteers)

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (MET55)

Healthy Volunteers (Meningococcal Infection)

India, South Africa
Sanofi

Completed

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
University of Oxford
Novartis Vaccines

Completed

Understanding the Immune Response to Meningitis Vaccines

Meningitis | Septicemia

United Kingdom
Sanofi Pasteur, a Sanofi Company

Recruiting

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations

Meningitis | Meningococcal Infection

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

Healthy Volunteers (Meningococcal Infection)

Lebanon, Turkey
EuBiologics Co.,Ltd

Completed

Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Infection, Meningococcal

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam

Healthy Volunteers | Meningococcal Infection

Vietnam
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Healthy Volunteers | Meningococcal Immunisation

Spain, Finland, Germany, Hungary
Sanofi Pasteur, a Sanofi Company

Completed

A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study

Meningococcal Immunization
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

Meningococcal Infection (Healthy Volunteers)

Puerto Rico, United States
EuBiologics Co.,Ltd

Completed

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Infection, Meningococcal

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41)

Healthy Volunteers (Meningococcal Infection)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Healthy Volunteers | Meningococcal Immunisation

Spain, Hungary, Italy, Singapore
GlaxoSmithKline

Completed

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Meningococcal Infections | Neisseria Meningitidis

Saudi Arabia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

Meningitis | Meningococcal Disease

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Russian Federation
Beijing Minhai Biotechnology Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine

Meningitis

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age

Meningitis | Meningococcal Infection

United States
Pfizer

Active, not recruiting

Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT)

Alopecia Areata

United States, Spain, China, Korea, Republic of, Taiwan, Australia, Canada, Germany, Czechia, Poland, Japan, United Kingdom, Mexico, Argentina, Chile, Colombia, Russian Federation
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Meningococcal Immunisation

United States, Puerto Rico
GlaxoSmithKline

Completed

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Respiratory Syncytial Virus Infections

Finland, Spain, United Kingdom, United States, Thailand, Brazil, Canada, Panama, Italy, Colombia, Mexico, Poland, Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
GlaxoSmithKline

Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Completed

Maternal Flu Vaccine Trial in Bamako, Mali

Influenza

Mali
JN-International Medical Corporation

Completed

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)

Healthy Volunteers (Meningococcal Infection)

United Kingdom
JN-International Medical Corporation

Completed

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

Meningococcal Infections | Meningococcal Meningitis

United States
CanSino Biologics Inc.

Recruiting

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Meningococcal Meningitis

Indonesia
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

Virus Diseases

Mali, Senegal

3

Subscribe